Investigation and analysis of the application of core outcomes in clinical trials of Chinese and Western medicine on myocardial infarction_Chinese Journal of Evidence-Based Medicine

Authors：

CHEN Zhuo ^1,2 , WAN Siqi ³ , GUAN Zhiyue ^1,2 , ZHANG Xinyi ^1,2 , LIU Shuling ^1,2 , WANG Wenhui ⁴ ,  QIU Ruijin ^1,2 ,  SHANG Hongcai ^1,4,5

1. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Beijing University of Chinese Medicine, Beijing 100700, P. R. China;
2. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P. R. China;
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
4. Hunan University of Chinese Medicine, Changsha 410208, P. R. China;
5. Beijing University of Chinese Medicine Dongfang Hospital, Beijing 100078, P. R. China;

Corresponding author：

QIU Ruijin, Email: psddqxn@163.com; SHANG Hongcai, Email: shanghongcai@126.com

Keywords：

Core outcome set; Outcomes; Clinical trial; Methodology

DOI：

10.7507/1672-2531.202409141

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The use of core outcome sets reduces heterogeneity in the reporting of outcomes in clinical trials, increasing the value and significance of research. This paper first introduces and interprets “core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine”, in order to help Chinese researchers better understand and use it. Second, this study surveyed the use of core outcomes in clinical trials from January 1, 2023 to June 1, 2024, showing that 91% (10/11) of the 35 acute myocardial infarction clinical studies included reported core outcomes, and the median percentage of using core outcome sets was only 36% (4/11). As the publication time of the core outcome set is close to the literature search time, the understanding of domestic researchers about it is still unclear. Further research is needed to explore the application of core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine, providing a reference for its update and improvement.

1.	COMET. Core outcome measures in effectiveness trials.
2.	Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1. 0. Trials, 2017, 18(Suppl 3): 280.
3.	张莉, 张俊华, 陈静, 等. 中医药临床研究评价指标体系中应引入核心结局指标集概念. 2013.
4.	邱瑞瑾, 万思琦, 关之玥, 等. 核心指标集在循证中医药学研究中的应用价值及前景分析. 北京中医药, 2023, 42(5): 470-474.
5.	邱瑞瑾, 魏旭煦, 关之玥, 等. 中医药领域核心指标集研究现状及展望. 中国循证医学杂志, 2023, 23(2): 211-220.
6.	Hughes KL, Williamson PR, Young B. In-depth qualitative interviews identified barriers and facilitators that influenced chief investigators' use of core outcome sets in randomised controlled trials. J Clin Epidemiol, 2022, 144: 111-120.
7.	Matvienko-Sikar K, Avery K, Blazeby JM, et al. Use of core outcome sets was low in clinical trials published in major medical journals. J Clin Epidemiol, 2022, 142: 19-28.
8.	Karumbi J, Gorst S, Gathara D, et al. Awareness and experiences on core outcome set development and use amongst stakeholders from low- and middle- income countries: an online survey. PLOS Glob Public Health, 2023, 3(12): e0002574.
9.	Qiu R, Fan X, Wang W, et al. Uptake of core outcome sets by clinical trialists in China: a protocol. F1000Res, 2024, 12: 1030.
10.	Qiu R, Wan S, Zhong C, et al. Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine. J Evid Based Med, 2024, 17(1): 86-94.
11.	Benstoem C, Moza A, Meybohm P, et al. A core outcome set for adult cardiac surgery trials: a consensus study. PLoS One, 2017, 12(11): e0186772.
12.	McNamara RL, Spatz ES, Kelley TA, et al. Standardized outcome measurement for patients with coronary artery disease: consensus from the international consortium for health outcomes measurement (ICHOM). J Am Heart Assoc, 2015, 4(5): e001767.
13.	邱瑞瑾, 孙杨, 胡嘉元, 等. 临床研究中选择结局指标测量工具的方法. 中国循证医学杂志, 2018, 18(2): 238-243.
14.	Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a "core outcome set" - a practical guideline. Trials, 2016, 17(1): 449.
15.	杨继, 张垚, 张运娇, 等. 基于主成分分析的中医药治疗慢性心力衰竭临床随机对照试验核心结局指标研究. 中西医结合心脑血管病杂志, 2021, 19(15): 2496-2509, 2515.
16.	孙亚男, 何丽云, 雒琳, 等. 中医药治疗慢性乙型肝炎临床试验的核心结局指标集研究. 中华中医药杂志, 2020, 35(9): 4684-4688.
17.	谢倩文, 肖晶旻, 邓雪仪, 等. 建立中医药治疗缺血性卒中核心结局指标集的初步研究. 中医杂志, 2022, 63(3): 220-228.
18.	邱瑞瑾, 孙杨, 钟长鸣, 等. 中医核心证候指标集的构建思路. 中国循证医学杂志, 2021, 21(11): 1353-1357.
19.	邱瑞瑾, 张心怡, 刘姝伶, 等. 临床研究结局指标报告指南解读及其对中医药领域研究的意义及启示. 中国循证医学杂志, 2024, 24(1): 119-124.
20.	Dirr MA, Ahmed A, Schlessinger DI, et al. Rosacea core domain set for clinical trials and practice: a consensus statement. JAMA Dermatol, 2024, 160(6): 658-666.
21.	中国临床试验注册中心.
22.	ClicalTrials. gov.
23.	中华中医药学会. T1级和T2级中医药中文科技期刊分级目录的期刊名单.
24.	中华医学会. 关于对第二批分领域发布我国高质量科技期刊分级目录进行公示的通知. 2020.
25.	刘琪, 蔡新勇, 詹宇亮, 等. 冠状动脉内应用不同剂量重组人尿激酶原的疗效及安全性. 中国介入心脏病学杂志, 2023, 31(9): 679-687.
26.	中国急性心肌梗死注册研究组. 匹伐他汀与阿托伐他汀对急性心肌梗死伴糖代谢异常患者血脂与血糖水平影响的对比研究. 中国循环杂志, 2023, 38(9): 930-936.
27.	张标, 杨静静, 赵德轩, 等. 芪参益气滴丸对T2DM合并AMI病人PCI术后心功能的影响. 中西医结合心脑血管病杂志, 2023, 21(16): 3041-3046.
28.	杨永强, 吴婷玉, 姜子超, 等. 麝香通心滴丸对STEMI急诊PCI围术期病人冠状动脉微循环及心肌梗死面积的影响. 中西医结合心脑血管病杂志, 2023, 21(10): 1881-1885.
29.	雷金义, 夏裕, 欧晓红. 芪参益气滴丸对急性心肌梗死经皮冠状动脉介入术后患者临床疗效的影响. 广州中医药大学学报, 2024, 41(4): 835-839.
30.	钱赓, 陈思, 姜潇思, 等. 注射用尼可地尔对于急性心肌梗死患者直接经皮冠状动脉介入治疗后对比剂肾病预防效果的临床研究. 中国介入心脏病学杂志, 2024, 32(3): 136-140.
31.	高景芳, 李莉, 耿学斌, 等. 重组人尿激酶原对ST段抬高型心肌梗死患者急诊介入治疗术后无复流现象及预后的影响. 中华老年心脑血管病杂志, 2024, 26(4): 385-388.
32.	Delewi R, Vogel RF, Wilschut JM, et al. Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction. Am Heart J, 2023, 258: 17-26.
33.	Amano M, Izumi C, Watanabe H, et al. Effects of long-term carvedilol therapy in patients with ST-segment elevation myocardial infarction and mildly reduced left ventricular ejection fraction. Am J Cardiol, 2023, 199: 50-58.
34.	Jering KS, Claggett BL, Pfeffer MA, et al. Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circ Heart Fail, 2023, 16(5): e010259.
35.	Hong SJ, Lee SJ, Suh Y, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation, 2024, 149(8): 562-573.
36.	Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation, 2023, 147(2): 108-117.
37.	Van de Werf F, Ristić AD, Averkov OV, et al. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial. Circulation, 2023, 148(9): 753-764.
38.	Harrington J, Udell JA, Jones WS, et al. Baseline characteristics of patients enrolled in the EMPACT-MI trial. Eur J Heart Fail, 2023, 25(9): 1708-1715.
39.	Lee M, Byun S, Lim S, et al. Dual antiplatelet therapy de-escalation in stabilized myocardial infarction with high ischemic risk: post hoc analysis of the TALOS-AMI randomized clinical trial. JAMA Cardiol, 2024, 9(2): 125-133.
40.	Behnes M, Lahu S, Ndrepepa G, et al. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. Clin Res Cardiol, 2023, 112(4): 518-528.
41.	Chen P, Eikelboom JW, Tan C, et al. Single bolus r-SAK before primary PCI for ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv, 2024, 17(2): e013455.
42.	Povsic TJ, Korjian S, Bahit MC, et al. Effect of reconstituted human apolipoprotein A-I on recurrent ischemic events in survivors of acute MI. J Am Coll Cardiol, 2024, 83(22): 2163-2174.
43.	Yan Y, Guo J, Wang X, et al. Postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction: a multicenter, randomized, double-blind trial. Circulation, 2024, 149(16): 1258-1267.
44.	Bulluck H, Chong JH, Bryant J, et al. Effect of cangrelor on infarct size in ST-segment-elevation myocardial infarction treated by primary percutaneous coronary intervention: a randomized controlled trial (the PITRI trial). Circulation, 2024, 150(2): 91-101.
45.	Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet, 2024, 403(10439): 1866-1878.
46.	Cao X, Dong Y, Yu H, et al. The effect of sitting baduanjin in patients with ST-segment elevation acute myocardial infarction after percutaneous coronary intervention: a quasi-experimental study. Heart Lung, 2024, 66: 78-85.
47.	中国临床试验注册中心. 补阳还五汤加味对PCI术后气虚血瘀型急性心肌梗死患者心室重构的影响. ChiCTR2400084722.
48.	中国临床试验注册中心. 肺部超声指导急性心肌梗死患者预防性使用利尿剂对亚临床心衰的随机对照研究. ChiCTR2400084523.
49.	中国临床试验注册中心. SGLT2抑制剂对急性心肌梗死患者心脏自主神经功能及预后的影响研究. ChiCTR2400084050.
50.	中国临床试验注册中心. 麝香通心滴丸在急性st段抬高型心肌梗死治疗中的价值. ChiCTR2400080728.
51.	中国临床试验注册中心. 麝香通心滴丸抑制急性心肌梗死后程序性坏死、改善预后的研究. ChiCTR2400080698.
52.	中国临床试验注册中心. 速效救心丸治疗急性ST段抬高型心肌梗死(气滞血瘀证)疗效与机制研究. ChiCTR2400080278.
53.	中国临床试验注册中心. 尼可地尔对急性心肌梗死行直接经皮冠状动脉介入治疗患者炎症反应的调节作用. ChiCTR2400080253.
54.	中国临床试验注册中心. 针灸对急性心肌梗死后冠状动脉微血管功能障碍的疗效评价: 随机对照试验研究方案(ACU-AMI试验). ChiCTR2400079603.
55.	中国临床试验注册中心. 针刺辅助治疗STEMI-PCI术后患者的循证评价. ChiCTR2400081117.
56.	ClicalTrials. gov. Henagliflozin reducing infarct size after priamry pci in patients with ST segment elevation myocardial infarction (Health).
57.	ClicalTrials. gov. TADCLOT- a double blind randomized controlled trial (TADCLOT).
58.	ClicalTrials. gov. Pleiotropic effects of dapagliflozin in patients with acute coronary syndromes.
59.	ClicalTrials. gov. Intravascular imaging study of the effect of inclisiran on plaque in patients with acute myocardial infarction (V-ACCELERATE).
60.	Dodd S, Gorst SL, Young A, et al. Patient participation impacts outcome domain selection in core outcome sets for research: an updated systematic review. J Clin Epidemiol, 2023, 158: 127-133.
61.	Kirkham JJ, Gorst S, Altman DG, et al. Core outcome set-standards for reporting: the COS-STAR statement. PLoS Med, 2016, 13(10): e1002148.
62.	Gargon E, Williamson PR, Blazeby JM, et al. Improvement was needed in the standards of development for cancer core outcome sets. J Clin Epidemiol, 2019, 112: 36-44.
63.	Goren K, Monsour A, Stallwood E, et al. Pediatric core outcome sets had deficiencies and lacked child and family input: a methodological review. J Clin Epidemiol, 2023, 155: 13-21.
64.	Williamson PR, Barrington H, Blazeby JM, et al. Review finds core outcome set uptake in new studies and systematic reviews needs improvement. J Clin Epidemiol, 2022, 150: 154-164.
65.	Li W, Li G, Chi H, et al. Uptake of the core outcome set on polycystic ovary syndrome before and after its publication. Hum Reprod, 2023, 38(9): 1816-1824.
66.	Kirkham JJ, Clarke M, Williamson PR. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials. gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ, 2017, 357: j2262.
67.	Kirkham JJ, Bracken M, Hind L, et al. Industry funding was associated with increased use of core outcome sets. J Clin Epidemiol, 2019, 115: 90-97.

1. COMET. Core outcome measures in effectiveness trials.
2. Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1. 0. Trials, 2017, 18(Suppl 3): 280.
3. 张莉, 张俊华, 陈静, 等. 中医药临床研究评价指标体系中应引入核心结局指标集概念. 2013.
4. 邱瑞瑾, 万思琦, 关之玥, 等. 核心指标集在循证中医药学研究中的应用价值及前景分析. 北京中医药, 2023, 42(5): 470-474.
5. 邱瑞瑾, 魏旭煦, 关之玥, 等. 中医药领域核心指标集研究现状及展望. 中国循证医学杂志, 2023, 23(2): 211-220.
6. Hughes KL, Williamson PR, Young B. In-depth qualitative interviews identified barriers and facilitators that influenced chief investigators' use of core outcome sets in randomised controlled trials. J Clin Epidemiol, 2022, 144: 111-120.
7. Matvienko-Sikar K, Avery K, Blazeby JM, et al. Use of core outcome sets was low in clinical trials published in major medical journals. J Clin Epidemiol, 2022, 142: 19-28.
8. Karumbi J, Gorst S, Gathara D, et al. Awareness and experiences on core outcome set development and use amongst stakeholders from low- and middle- income countries: an online survey. PLOS Glob Public Health, 2023, 3(12): e0002574.
9. Qiu R, Fan X, Wang W, et al. Uptake of core outcome sets by clinical trialists in China: a protocol. F1000Res, 2024, 12: 1030.
10. Qiu R, Wan S, Zhong C, et al. Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine. J Evid Based Med, 2024, 17(1): 86-94.
11. Benstoem C, Moza A, Meybohm P, et al. A core outcome set for adult cardiac surgery trials: a consensus study. PLoS One, 2017, 12(11): e0186772.
12. McNamara RL, Spatz ES, Kelley TA, et al. Standardized outcome measurement for patients with coronary artery disease: consensus from the international consortium for health outcomes measurement (ICHOM). J Am Heart Assoc, 2015, 4(5): e001767.
13. 邱瑞瑾, 孙杨, 胡嘉元, 等. 临床研究中选择结局指标测量工具的方法. 中国循证医学杂志, 2018, 18(2): 238-243.
14. Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a "core outcome set" - a practical guideline. Trials, 2016, 17(1): 449.
15. 杨继, 张垚, 张运娇, 等. 基于主成分分析的中医药治疗慢性心力衰竭临床随机对照试验核心结局指标研究. 中西医结合心脑血管病杂志, 2021, 19(15): 2496-2509, 2515.
16. 孙亚男, 何丽云, 雒琳, 等. 中医药治疗慢性乙型肝炎临床试验的核心结局指标集研究. 中华中医药杂志, 2020, 35(9): 4684-4688.
17. 谢倩文, 肖晶旻, 邓雪仪, 等. 建立中医药治疗缺血性卒中核心结局指标集的初步研究. 中医杂志, 2022, 63(3): 220-228.
18. 邱瑞瑾, 孙杨, 钟长鸣, 等. 中医核心证候指标集的构建思路. 中国循证医学杂志, 2021, 21(11): 1353-1357.
19. 邱瑞瑾, 张心怡, 刘姝伶, 等. 临床研究结局指标报告指南解读及其对中医药领域研究的意义及启示. 中国循证医学杂志, 2024, 24(1): 119-124.
20. Dirr MA, Ahmed A, Schlessinger DI, et al. Rosacea core domain set for clinical trials and practice: a consensus statement. JAMA Dermatol, 2024, 160(6): 658-666.
21. 中国临床试验注册中心.
22. ClicalTrials. gov.
23. 中华中医药学会. T1级和T2级中医药中文科技期刊分级目录的期刊名单.
24. 中华医学会. 关于对第二批分领域发布我国高质量科技期刊分级目录进行公示的通知. 2020.
25. 刘琪, 蔡新勇, 詹宇亮, 等. 冠状动脉内应用不同剂量重组人尿激酶原的疗效及安全性. 中国介入心脏病学杂志, 2023, 31(9): 679-687.
26. 中国急性心肌梗死注册研究组. 匹伐他汀与阿托伐他汀对急性心肌梗死伴糖代谢异常患者血脂与血糖水平影响的对比研究. 中国循环杂志, 2023, 38(9): 930-936.
27. 张标, 杨静静, 赵德轩, 等. 芪参益气滴丸对T2DM合并AMI病人PCI术后心功能的影响. 中西医结合心脑血管病杂志, 2023, 21(16): 3041-3046.
28. 杨永强, 吴婷玉, 姜子超, 等. 麝香通心滴丸对STEMI急诊PCI围术期病人冠状动脉微循环及心肌梗死面积的影响. 中西医结合心脑血管病杂志, 2023, 21(10): 1881-1885.
29. 雷金义, 夏裕, 欧晓红. 芪参益气滴丸对急性心肌梗死经皮冠状动脉介入术后患者临床疗效的影响. 广州中医药大学学报, 2024, 41(4): 835-839.
30. 钱赓, 陈思, 姜潇思, 等. 注射用尼可地尔对于急性心肌梗死患者直接经皮冠状动脉介入治疗后对比剂肾病预防效果的临床研究. 中国介入心脏病学杂志, 2024, 32(3): 136-140.
31. 高景芳, 李莉, 耿学斌, 等. 重组人尿激酶原对ST段抬高型心肌梗死患者急诊介入治疗术后无复流现象及预后的影响. 中华老年心脑血管病杂志, 2024, 26(4): 385-388.
32. Delewi R, Vogel RF, Wilschut JM, et al. Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction. Am Heart J, 2023, 258: 17-26.
33. Amano M, Izumi C, Watanabe H, et al. Effects of long-term carvedilol therapy in patients with ST-segment elevation myocardial infarction and mildly reduced left ventricular ejection fraction. Am J Cardiol, 2023, 199: 50-58.
34. Jering KS, Claggett BL, Pfeffer MA, et al. Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circ Heart Fail, 2023, 16(5): e010259.
35. Hong SJ, Lee SJ, Suh Y, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation, 2024, 149(8): 562-573.
36. Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation, 2023, 147(2): 108-117.
37. Van de Werf F, Ristić AD, Averkov OV, et al. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial. Circulation, 2023, 148(9): 753-764.
38. Harrington J, Udell JA, Jones WS, et al. Baseline characteristics of patients enrolled in the EMPACT-MI trial. Eur J Heart Fail, 2023, 25(9): 1708-1715.
39. Lee M, Byun S, Lim S, et al. Dual antiplatelet therapy de-escalation in stabilized myocardial infarction with high ischemic risk: post hoc analysis of the TALOS-AMI randomized clinical trial. JAMA Cardiol, 2024, 9(2): 125-133.
40. Behnes M, Lahu S, Ndrepepa G, et al. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. Clin Res Cardiol, 2023, 112(4): 518-528.
41. Chen P, Eikelboom JW, Tan C, et al. Single bolus r-SAK before primary PCI for ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv, 2024, 17(2): e013455.
42. Povsic TJ, Korjian S, Bahit MC, et al. Effect of reconstituted human apolipoprotein A-I on recurrent ischemic events in survivors of acute MI. J Am Coll Cardiol, 2024, 83(22): 2163-2174.
43. Yan Y, Guo J, Wang X, et al. Postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction: a multicenter, randomized, double-blind trial. Circulation, 2024, 149(16): 1258-1267.
44. Bulluck H, Chong JH, Bryant J, et al. Effect of cangrelor on infarct size in ST-segment-elevation myocardial infarction treated by primary percutaneous coronary intervention: a randomized controlled trial (the PITRI trial). Circulation, 2024, 150(2): 91-101.
45. Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet, 2024, 403(10439): 1866-1878.
46. Cao X, Dong Y, Yu H, et al. The effect of sitting baduanjin in patients with ST-segment elevation acute myocardial infarction after percutaneous coronary intervention: a quasi-experimental study. Heart Lung, 2024, 66: 78-85.
47. 中国临床试验注册中心. 补阳还五汤加味对PCI术后气虚血瘀型急性心肌梗死患者心室重构的影响. ChiCTR2400084722.
48. 中国临床试验注册中心. 肺部超声指导急性心肌梗死患者预防性使用利尿剂对亚临床心衰的随机对照研究. ChiCTR2400084523.
49. 中国临床试验注册中心. SGLT2抑制剂对急性心肌梗死患者心脏自主神经功能及预后的影响研究. ChiCTR2400084050.
50. 中国临床试验注册中心. 麝香通心滴丸在急性st段抬高型心肌梗死治疗中的价值. ChiCTR2400080728.
51. 中国临床试验注册中心. 麝香通心滴丸抑制急性心肌梗死后程序性坏死、改善预后的研究. ChiCTR2400080698.
52. 中国临床试验注册中心. 速效救心丸治疗急性ST段抬高型心肌梗死(气滞血瘀证)疗效与机制研究. ChiCTR2400080278.
53. 中国临床试验注册中心. 尼可地尔对急性心肌梗死行直接经皮冠状动脉介入治疗患者炎症反应的调节作用. ChiCTR2400080253.
54. 中国临床试验注册中心. 针灸对急性心肌梗死后冠状动脉微血管功能障碍的疗效评价: 随机对照试验研究方案(ACU-AMI试验). ChiCTR2400079603.
55. 中国临床试验注册中心. 针刺辅助治疗STEMI-PCI术后患者的循证评价. ChiCTR2400081117.
56. ClicalTrials. gov. Henagliflozin reducing infarct size after priamry pci in patients with ST segment elevation myocardial infarction (Health).
57. ClicalTrials. gov. TADCLOT- a double blind randomized controlled trial (TADCLOT).
58. ClicalTrials. gov. Pleiotropic effects of dapagliflozin in patients with acute coronary syndromes.
59. ClicalTrials. gov. Intravascular imaging study of the effect of inclisiran on plaque in patients with acute myocardial infarction (V-ACCELERATE).
60. Dodd S, Gorst SL, Young A, et al. Patient participation impacts outcome domain selection in core outcome sets for research: an updated systematic review. J Clin Epidemiol, 2023, 158: 127-133.
61. Kirkham JJ, Gorst S, Altman DG, et al. Core outcome set-standards for reporting: the COS-STAR statement. PLoS Med, 2016, 13(10): e1002148.
62. Gargon E, Williamson PR, Blazeby JM, et al. Improvement was needed in the standards of development for cancer core outcome sets. J Clin Epidemiol, 2019, 112: 36-44.
63. Goren K, Monsour A, Stallwood E, et al. Pediatric core outcome sets had deficiencies and lacked child and family input: a methodological review. J Clin Epidemiol, 2023, 155: 13-21.
64. Williamson PR, Barrington H, Blazeby JM, et al. Review finds core outcome set uptake in new studies and systematic reviews needs improvement. J Clin Epidemiol, 2022, 150: 154-164.
65. Li W, Li G, Chi H, et al. Uptake of the core outcome set on polycystic ovary syndrome before and after its publication. Hum Reprod, 2023, 38(9): 1816-1824.
66. Kirkham JJ, Clarke M, Williamson PR. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials. gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ, 2017, 357: j2262.
67. Kirkham JJ, Bracken M, Hind L, et al. Industry funding was associated with increased use of core outcome sets. J Clin Epidemiol, 2019, 115: 90-97.

Chinese Journal of Evidence-Based Medicine

Latest ArticlesInvestigation and analysis of the application of core outcomes in clinical trials of Chinese and Western medicine on myocardial infarction

Abstract Full text Figures/Tables Video References Cited by

Format

Content